Delivery Order SPE2DB22D9367-SPE2DB24FSZ41

Award Date 8/27/24
Potential Completion Date 9/18/24
Potential Value $7.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense (DoD). The $3,573.45 firm fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency. The $3,471.55 firm fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has an ultimate completion date of July 1, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $7,146.90, is a firm-fixed price delivery order with no set-aside designation. It was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense. The $8,576.28 firm fixed-price contract was awarded on July 17, 2024 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has an ultimate completion date of August 7, 2024 and is not designated as a set-aside. DMS Pharmaceutical Group Inc. holds a...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency. The $11,038.14 fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense (DoD). The contract, valued at $5,717.52, was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order with no set-aside designation, and it has an ultimate completion date of September 9, 2024. DMS...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency. The $6,248.79 firm fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has an ultimate completion date of March 18, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the Department of Defense (DoD). The contract, valued at $1,251.88, was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order and does not have a set-aside designation. DMS Pharmaceutical Group Inc. holds a significant single-award...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense (DoD). The contract, valued at $4,288.14, is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is part of a larger $499,999,999 indefinite delivery contract (IDC) that DMS Pharmaceutical Group holds with...
This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The contract was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order with a ceiling value of $17,152.56 and an ultimate completion date of October 18, 2024. DMS Pharmaceutical Group Inc. has a significant indefinite...
  • SPE2DB22D9367
    Indefinite Delivery Contract
  • SPE2DB22D9367-SPE2DB24FSZ41
    Delivery Order

This federal contract award is for the delivery of NEXPLANON 68 MG IMPLANTS to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense (DoD). The $7,146.90 firm fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois.

DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. Through this vehicle, DMS Pharmaceutical Group provides both routine and critical medications, including specialized drugs and medical supplies, to support the diverse medical requirements of military personnel and their dependents across various DoD healthcare facilities.

Generated 11/26/24, 9:06 AM